Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.78 USD | -5.01% | -10.78% | -30.99% |
Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.99% | 2.22B | |
-2.48% | 104B | |
+1.29% | 97.42B | |
+0.79% | 22.2B | |
-17.98% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-16.02% | 15.06B | |
+3.90% | 13.98B | |
+34.32% | 11.66B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Therapeutics Says FDA Placed Potential Treatment for Alzheimer's Place on Clinical Hold; Shares Decline Pre-Bell